More importantly, 17-AAG as a HSP90 inhibitor can improve the therapeutic outcome of cisplatin-based combination chemotherapy against advanced bladder cancer 8, and provide new approaches to prevent and treat castration-resistant prostate cancer 9, suggesting that 17-AAG may exert inhibitory effects on tumour development. This evidence concerns the gene HSP90AA1 and urinary bladder cancer.